Table 4.
Thyroid dysfunction | Obese individuals | Normal weight | Crude OR | Adjusted OR* | ||
---|---|---|---|---|---|---|
OR (95%CI) | P | OR (95%CI) | P | |||
Total | N = 397 | N = 1,366 | ||||
Hypothyroidism# | 55 (13.9%) | 170 (12.4%) | 1.13 (0.82–1.57) | 0.46 | 1.25 (0.86–1.80) | 0.24 |
SCH | 53 (13.3%) | 157 (11.5%) | 1.19 (0.85–1.66) | 0.32 | 1.31 (0.90–1.91) | 0.16 |
TAI | 49 (12.3%) | 181 (13.3%) | 0.92 (0.66–1.29) | 0.64 | 1.11 (0.76–1.61) | 0.60 |
TPOAb positivity | 38 (9.6%) | 114 (8.3%) | 1.03 (0.71–1.51) | 0.87 | 1.24 (0.81–1.91) | 0.32 |
TGAb positivity | 42 (10.6%) | 148 (10.8%) | 0.90 (0.63–1.30) | 0.58 | 1.29 (0.86–1.94) | 0.22 |
Men | N = 252 | N = 540 | ||||
Hypothyroidism# | 22 (8.7%) | 49 (%) | 0.96 (0.57–1.62) | 0.87 | 1.01 (0.56–1.80) | 0.98 |
SCH | 21 (8.3%) | 47 (9.1%) | 0.95 (0.56–1.63) | 0.86 | 1.01 (0.56–1.83) | 0.97 |
TAI | 22 (8.7%) | 34 (6.3%) | 1.42 (0.81–2.49) | 0.21 | 1.27 (0.68–2.35) | 0.45 |
TPOAb positivity | 16 (6.3%) | 19 (3.5%) | 1.52 (0.79–2.94) | 0.21 | 1.30 (0.63–2.68) | 0.48 |
TGAb positivity | 17 (6.7%) | 22 (4.1%) | 1.56 (0.82–2.95) | 0.18 | 1.54 (0.75–3.19) | 0.24 |
Women | N = 145 | N = 826 | ||||
Hypothyroidism# | 33 (22.7%) | 121 (14.6%) | 1.72 (1.11–2.65) | 0.015 | 1.50 (0.93–2.42) | 0.09 |
SCH | 32 (22.1%) | 110 (13.3%) | 1.84 (1.19–2.86) | 0.007 | 1.63 (1.00–2.65) | 0.048 |
TAI | 27 (18.6%) | 147 (17.8%) | 1.06 (0.67–1.66) | 0.81 | 1.01 (0.62–1.65) | 0.96 |
TPOAb positivity | 22 (15.2%) | 95 (11.5%) | 1.24 (0.75–2.04) | 0.39 | 1.16 (0.68–2.00) | 0.58 |
TGAb positivity | 25 (17.2%) | 126 (15.3%) | 1.08 (0.67–1.72) | 0.76 | 1.18 (0.71–1.95) | 0.52 |
Confounding factors in the multiple logistic regression analysis included age, sex, smoking, diabetes, hypertension, salt type and urinary iodine concentration.
Hypothyroidism included SCH and overt hypothyroidism. OR, odds ratio; 95%CI, 95% confidence interval. Bold values were statistically significant outcomes.